U.S. Markets close in 1 hr 32 mins

Selecta Biosciences, Inc. (SELB)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.9000+0.0700 (+3.83%)
As of 02:25PM EST. Market open.

Selecta Biosciences, Inc.

65 Grove Street
Watertown, MA 02472
United States
617 923 1400

Full Time Employees58

Key Executives

NameTitlePayExercisedYear Born
Dr. Carsten Brunn Ph.D.CEO, Pres & Director883.08kN/A1971
Ms. Ann K. Donohue CPAVP of Fin. & Controller286.97kN/A1982
Mr. Kevin TanChief Financial Officer515.14kN/A1977
Dr. Lloyd Johnston Ph.D.Chief Operating Officer564.12kN/A1968
Dr. Takashi Kei Kishimoto Ph.D.Chief Scientific Officer565.95kN/A1960
Dr. Peter G. Traber M.D.Chief Medical Officer642.56kN/A1955
Dr. Ulrich H. von Andrian-Werburg M.D., Ph.D.Co-Founder and Co-Chair of the Scientific Advisory BoardN/AN/AN/A
Mr. Matthew Bartholomae J.D.Gen. Counsel & Sec.N/AN/AN/A
Ms. Kristen BaldwinChief People OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Corporate Governance

Selecta Biosciences, Inc.’s ISS Governance QualityScore as of October 1, 2022 is 8. The pillar scores are Audit: 8; Board: 7; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.